SPC News Staff
A pivotal phase 3 trial of dupilumab (Dupixent, Regeneron) met its primary and all key secondary end points in children aged 6 to 11 years with uncontrolled moderate to severe asthma, according to Sanofi, the parent company.
In a broad type 2 inflammatory asthma patient population, defined as having elevated eosinophils (EOS) or elevated fractional exhaled nitric oxide (FeNO), dupilumab added to standard-of-care treatment significantly reduced asthma exacerbations and